Benefits
Biological age markers in an uncontrolled study
A longitudinal observational study followed 42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months and reported an average 8-year drop in a DNA methylation age estimate over 7 months. DNA methylation clocks are research tools, not validated clinical endpoints, so a change in a clock reading is not the same as a change in health, function or lifespan. Critical caveats: self-reported, no placebo control, single methylation clock, possible selection bias, small sample, and Ca-AKG combined with vitamins (cannot attribute to AKG alone). Hypothesis-generating, not confirmatory. A later cross-sectional analysis of 4,260 people who bought saliva epigenetic tests found the same delayed-release Ca-AKG plus vitamin product associated with a 1.8-year lower age residual, which is far smaller than 8 years, while plain AKG showed no significant association at all. That analysis is also uncontrolled and open to healthy-user bias.
Randomized trial of Ca-AKG has not reported yet
The Able trial (National University of Singapore Phase 2 RCT) is testing Ca-AKG vs placebo for 6 months in 120 middle-aged adults (40-60 years) with biological age higher than chronological age. Its primary outcome is change in DNA methylation age. Recruitment is finished and all 120 participants were enrolled, and the registry gives a primary completion date of August 2025, but as of August 2026 no results have been published and none are posted on the trial registry, which still lists the study as active and not recruiting with completion estimated for January 2027. Until those results appear this is a study in progress, not a benefit of taking AKG, and the biological age question should be treated as open.
Animal lifespan extension across multiple species
AKG extends lifespan in fruit flies, C. elegans roundworms, and mice. A mouse study showed Ca-AKG reduced frailty and enhanced longevity (compression of morbidity). Mechanism: caloric restriction mimetic via inhibiting ATP synthase and TOR, activating AMPK. Foundational preclinical evidence supporting human longevity research interest. Worth saying plainly: no comparable lifespan or healthspan result has been shown in people, and lifespan extension in short-lived laboratory species has a poor record of carrying over to humans.
Bone density and strength support
Animal studies and one human trial have tested whether Ca-AKG supports bone. The human result landed on bone turnover rather than on bone density. Mechanism: stimulates collagen synthesis (proline hydroxylation requires AKG cofactor) and provides calcium for mineralization. The specific evidence is one randomized double-blind 6-month trial in 76 postmenopausal women with osteopenia, comparing calcium AKG supplying 6 g of AKG per day against the same amount of calcium alone. The bone resorption marker CTX fell by up to 37 percent in the AKG group, with a significant difference from the calcium-only group at 12 and 24 weeks. Because the comparator was calcium alone, that change is attributable to the AKG and not to the calcium it carries. Three limits belong alongside it: osteocalcin did not change, the between-group difference in lumbar spine bone mineral density was 0.9 percent and not statistically significant, and the dose was six times what a typical 1 g Ca-AKG longevity product supplies.
Wound healing and protein synthesis
Older clinical research tested ornithine alpha-ketoglutarate, a different compound from the calcium AKG sold as a supplement, and showed it improves nitrogen balance in surgical patients and burn victims. In severe burn patients it shortened wound healing time and reduced markers of protein breakdown. Mechanism via amino acid synthesis support and growth hormone secretion. Clinical use in some European hospitals as nutritional adjunct. Read this as borrowed evidence rather than a claim for a consumer product. The compound is ornithine AKG, not calcium AKG; the dose was 10 to 30 g per day; it was delivered by feeding tube as part of hospital nutrition; and the patients had burns over a quarter or more of their body surface. None of it has been tested in healthy people taking 1 g of Ca-AKG by mouth.
Muscle protein synthesis support (preclinical)
AKG provides nitrogen carriers for amino acid synthesis (transamination reactions), supporting muscle protein synthesis and reducing protein catabolism in stress states. Animal evidence supports anabolic effects, and the human tests point in both directions. Single-dose trials of arginine alpha-ketoglutarate found nothing: one in resistance-trained and untrained men showed no gain in one-repetition maximum or total load volume on bench or leg press, a second found no improvement in muscular endurance with participants completing slightly fewer chin-ups and total repetitions on the supplement than on placebo, and a third found no added blood flow or nitric oxide response after resistance exercise beyond what the exercise itself produced. One longer study is positive: 12 g/day of arginine alpha-ketoglutarate over 8 weeks of resistance training in 35 men aged 30 to 50 improved bench press one-repetition maximum and peak anaerobic power, with no change in body composition, quadriceps endurance or aerobic capacity. All of these used the arginine salt rather than calcium AKG, the positive trial was small, and its gains were limited to two of the many measures taken, so the fair summary is that a muscle benefit from oral AKG in healthy people is unsettled rather than established.
Mechanism of action
TCA cycle intermediate (energy metabolism)
AKG is one of eight TCA cycle intermediates — converted to succinyl-CoA via α-ketoglutarate dehydrogenase. Critical for glucose, fatty acid, and amino acid oxidation. Energy production substrate. Provides direct metabolic support for cellular energy demands.
Substrate for dioxygenases (epigenetic regulation)
AKG is a required cofactor for 2-OG-dependent dioxygenases, including TET enzymes (DNA demethylation), JmjC histone demethylases (chromatin modification), prolyl hydroxylases (collagen synthesis, HIF regulation), and many others. Supplementation may support epigenetic regulation, a proposed mechanism for the observed biological age effects.
Caloric restriction mimetic via ATP synthase / TOR / AMPK
Animal studies show AKG inhibits ATP synthase and TOR (target of rapamycin) signaling while activating AMPK pathway — mimicking effects of caloric restriction (the most reliable known longevity intervention in animals). Mechanism for lifespan extension observed in flies, worms, mice.
Glutamate-glutamine cycling and nitrogen metabolism
AKG combines with ammonia via glutamate dehydrogenase to form glutamate — central nitrogen disposal pathway. Used clinically (post-surgery) to manage nitrogen balance and support amino acid synthesis. Mechanism for protein-anabolic effects in catabolic states.
Calcium delivery (Ca-AKG specifically)
Ca-AKG salt provides both alpha-ketoglutarate and calcium — useful for bone health and as practical delivery mechanism. Calcium AKG enhances oral stability and bioavailability vs free AKG. The one human bone trial separated the two components: it compared calcium AKG against an equal amount of calcium alone, so the fall in bone turnover it reported is attributable to the AKG rather than to the calcium the salt carries. Bone mineral density itself did not differ significantly between the two groups, so the calcium delivery is better described as a practical feature of the salt than as a proven bone density benefit.
Clinical trials
Longitudinal observational study (Demidenko O, Barardo D, Budovskii V, Finnemore R, Palmer FR 3rd, Kennedy BK, Budovskaya YV 2021, Aging 13(22):24485-24499, doi:10.18632/aging.203736).
42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months. Biological age measured by TruAge DNA methylation test (Horvath-derived clock) before/during/after treatment.
Average 8-YEAR reduction in biological age (TruAge DNA methylation) over average 7 months Rejuvant supplementation. Substantial effect if real. Critical caveats: (1) observational/uncontrolled design, no placebo, (2) self-reported subjects with potential selection bias, (3) single DNA methylation clock, (4) Rejuvant is combination product (AKG + vitamins), (5) sponsored by Ponce de Leon Health (commercial interest), (6) small sample. Most-cited human evidence for AKG biological age effects but methodologically limited.
Mouse longevity study (Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley CD, Gan G, Kim DE, Kasler HG, Kuehnemann C, Kaplowitz B, Bhaumik D, Riley RR, Kennedy BK, Lithgow GJ 2020, Cell Metab 32(3):447-456.e6, doi:10.1016/j.cmet.2020.08.004).
C57BL/6 mice received Ca-AKG supplementation. Frailty, lifespan, and healthspan measured.
Ca-AKG reduced frailty and enhanced longevity in mice — compression of morbidity (mice lived longer and with less age-related decline). The mechanism the authors propose is that dietary AKG induces the anti-inflammatory cytokine IL-10, which then suppresses chronic inflammation. Note the direction: IL-10 went up, not down. Several of the investigators disclose equity in the company that sells the Ca-AKG longevity product. Foundational animal evidence supporting Ca-AKG's emergence as 'longevity supplement.' Critical mouse-to-human translation gap — animal lifespan studies do not reliably predict human supplementation effects.
Phase 2 randomized double-blind placebo-controlled trial (NCT05706389). National University of Singapore.
120 healthy middle-aged adults (40-60 years) with biological age higher than chronological age. Randomized to Ca-AKG or placebo for 6 months. Primary outcome: biological age change.
No results. All 120 participants were enrolled and the registry gives a primary completion date of August 2025, but as of August 2026 no results paper has appeared and no results are posted on the registry, which still lists the study as active and not recruiting with completion estimated for January 2027. The only published output so far is a recruitment feasibility report. This entry therefore describes a study design, not a finding, and nothing in it should be read as evidence that Ca-AKG lowers biological age. One correction to the earlier framing: the trial is not fully independent of commercial interest, since one of its investigators has served on the scientific advisory board of the company selling the Ca-AKG product.